|1.||Brem, Henry: 24 articles (08/2015 - 02/2002)|
|2.||Friedman, Henry S: 12 articles (08/2009 - 05/2002)|
|3.||Gerson, Stanton L: 11 articles (11/2015 - 04/2002)|
|4.||Olivi, Alessandro: 11 articles (08/2015 - 04/2003)|
|5.||Weingart, Jon D: 8 articles (08/2015 - 03/2003)|
|6.||Wei, Kuo-Chen: 8 articles (03/2015 - 01/2005)|
|7.||Ross, Brian D: 8 articles (11/2010 - 12/2004)|
|8.||Rehemtulla, Alnawaz: 8 articles (11/2010 - 12/2004)|
|9.||Tyler, Betty M: 8 articles (03/2010 - 11/2002)|
|10.||Tyler, Betty: 7 articles (01/2015 - 02/2002)|
01/01/1988 - "Among these drugs, only a relatively low dose of BCNU (15-20 mg/kg) was effective in curing most mice (85%) bearing a large, late stage tumor. "
03/01/2015 - "In tumor-bearing animals, BCNU bubbles with FUS showed significant control of tumor progression and improved maximum survival from 26 to 35 days. "
08/01/1985 - "Furthermore, LSA tumor cells that failed to evoke tumor-specific CTL activity in normal mice could induce high CTL activity in BCNU-cured mice. "
04/01/1981 - "Treatment with BCNU 1 hour before or 1 day after neutron irradiation proved to be no more effective in proving the survival time of tumor-bearing animals than the drug similarly combined with conventional gamma irradiation."
11/15/1996 - "BCNU and XRT together were effective against all four tumors. "
10/01/2010 - "Randomized phase III trials have shown significant improvement of survival 1, 2, and 3 years after implantation of 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) wafers for patients with newly diagnosed malignant glioma. "
10/01/2010 - "Combining these techniques significantly improved the delivery of 1,3-bis(2-chloroethyl)-1-nitrosourea to rodent gliomas. "
01/15/1998 - "Treatment with radiation, IFN-a, and BCNU is feasible and effective in patients with high-grade gliomas, although constitutional symptoms from IFN-a are substantial."
09/01/1984 - "Because of the rapid systemic clearance of BCNU (1,3-bis-(2-chloroethyl)-1-nitrosourea), intra-arterial administration should provide a substantial advantage over intravenous administration for the treatment of malignant gliomas. "
05/01/1992 - "It is concluded that intra-arterial BCNU is neither safe nor effective in prolonging survival when administered by the methods used in this study of newly diagnosed patients with malignant glioma."
|3.||Glioblastoma (Glioblastoma Multiforme)
01/01/2015 - "The study investigated if intraoperative use of carmustine wafers, particularly in combination with Stupp regimen, is a viable and safe first-line treatment option of glioblastomas. "
01/01/2015 - "The intraoperative use of carmustine wafers in combination with Stupp regimen is a viable first-line treatment option of glioblastomas. "
01/01/2015 - "Combining intraoperative carmustine wafers and Stupp regimen in multimodal first-line treatment of primary glioblastomas."
09/01/2011 - "The efficacy of carmustine wafers for older patients with glioblastoma multiforme: prolonging survival."
02/01/2008 - "Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme."
|4.||Brain Neoplasms (Brain Tumor)
04/01/2011 - "Anti-EGFR/BCNU-CASLNs demonstrated the properties including an effective delivery to U87MG cells and antiproliferative efficacy against the growth of malignant brain tumors."
10/01/1982 - "This preliminary study was undertaken to identify the combined efficacy of perfluorochemicals (Fluosol-43) and a chemotherapeutic agent (BCNU) in a rat brain tumor model. "
08/01/2004 - "As part of a Pediatric Oncology Group Phase I study, 120 mg/m(2) of O(6)BG was administered i.v. over 1 h, before 1,3-bis(2-chloroethyl)-1-nitrosourea administration in children with recurrent or refractory brain tumors. "
08/27/1999 - "This paper reports the development of three-dimensional simulations to study the effect of various factors on the delivery of 1-3-bis(2-chloroethyl)-1-nitrosourea (BCNU) to brain tumors. "
04/01/1996 - "The aim of our study is to characterize the disturbance induced by repeated BCNU treatments in 12 human brain tumor cell lines in terms of their collective behavior. "
09/01/2015 - "LDE-carmustine was shown to be safe and effective in a drug combination protocol, which encourages larger studies to investigate the use of this novel formulation to treat canine lymphomas. "
01/01/1984 - "Adoptive transfer of immunity by spleen cells from LSA-lymphoma mice cured by BCNU."
08/26/2015 - "Recently, mainly due to the unavailability of carmustine, several novel conditioning protocols have been clinically developed, with the aim of improving the overall outcome by enhancing the anti-lymphoma effect and, at the same time, by reducing short and long-term toxicity. "
02/01/2011 - "BCNU at 300 mg/m(2) in a CBV regimen prior to PBSCT is well tolerated in relapsed or refractory pediatric lymphoma patients. "
12/01/1985 - "In radiation-induced lymphomas produced by 190 rad every week X 4 of 33 +/- 3 day old mice, spleen cell (X 1) therapy or BCNU treatment increased the MST of treated mice from 142 days to 177 days after iv spleen cells or to 195 days after iv-ip spleen cells, and this protocol produced 31% long-term cures. "
|3.||Etoposide (VP 16)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)
|4.||Combination Drug Therapy (Combination Chemotherapy)
|5.||Bone Marrow Transplantation (Transplantation, Bone Marrow)